Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination

Prathit A. Kulkarni, Vinay Prasad

PDF(72 KB)
PDF(72 KB)
Front. Med. ›› 2021, Vol. 15 ›› Issue (6) : 938-941. DOI: 10.1007/s11684-021-0895-9
COMMENT

Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination

Author information +
History +

Cite this article

Download citation ▾
Prathit A. Kulkarni, Vinay Prasad. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Front. Med., 2021, 15(6): 938‒941 https://doi.org/10.1007/s11684-021-0895-9

References

[1]
U.S. Centers for Disease Control & Prevention. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. Press release on April 13, 2021. 2021. https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html (accessed April 24, 2021)
[2]
U.S. Centers for Disease Control & Prevention. Health Alert Network Advisory on April 13, 2021. 2021. https://emergency.cdc.gov/han/2021/han00442.asp (accessed April 24, 2021)
[3]
U.S. Centers for Disease Control & Prevention. ACIP presentation slides: May 12, 2021 meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf (accessed August 2, 2021)
[4]
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(4): 1158–1192
CrossRef Pubmed Google scholar
[5]
Sánchez van Kammen M, Heldner MR, Brodard J, Scutelnic A, Silvis S, Schroeder V, Kremer Hovinga JA, Middeldorp S, Levi M, Hiltunen S, Lindgren E, Mansour M, Arauz A, Barboza MA, Zuurbier SM, Aguiar de Sousa D, Ferro JM, Fischer U, Field TS, Jood K, Tatlisumak T, Putaala J, Arnold M, Coutinho JM. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA 2021; 326(4): 332–338
CrossRef Pubmed Google scholar
[6]
U.S. Centers for Disease Control & Prevention. ACIP presentation slides: April 23, 2021 meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04-23.html (accessed April 24, 2021)
[7]
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021; 325(24): 2448–2456
CrossRef Pubmed Google scholar
[8]
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384(22): 2092–2101
CrossRef Pubmed Google scholar
[9]
Schultz NH, Sárvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384(22): 2124–2130
CrossRef Pubmed Google scholar
[10]
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19. N Engl J Med 2021; 384(23): 2202–2211
CrossRef Pubmed Google scholar
[11]
Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O, Mémier V, Geeraerts T, Marlu R, Pernod G, Mourey G, Fournel A, Cordonnier C, Susen S. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385(4): 376–378
CrossRef Pubmed Google scholar
[12]
U.S. Centers for Disease Control & Prevention. ACIP presentation slides: July 22, 2021 meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/05-COVID-Rosenblum-508.pdf(accessed August 2, 2021)
[13]
United Kingdom Joint Committee on Vaccination and Immunisation. Use of the AstraZeneca COVID-19 (AZD1222) vaccine: Updated JCVI statement, 7 May 2021. 2021. https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement-7-may-2021/use-of-the-astrazeneca-covid-19-azd1222-vaccine-updated-jcvi-statement-7-may-2021 (accessed August 2, 2021)
[14]
U.S. Centers for Disease Control & Prevention. ACIP presentation slides: July 22, 2021 meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/06-COVID-Mbaeyi-508.pdf (accessed August 2, 2021)

Compliance with ethics guidelines

Prathit A. Kulkarni discloses the following: Research funding: Vessel Health, Inc.; Michael E. DeBakey VA Medical Center Research Service Line; Department of Veterans Affairs Office of Research and Development; Speaking: National AIDS Education & Training Center.
Vinay Prasad disclosesthe following: Research funding: Arnold Ventures; Royalties: Johns Hopkins Press, Medscape, MedPage Today; Consulting: UnitedHealthcare; Speaking: Evicore, New Century Health; Other: Patreon backers for Plenary Session podcast.
This manuscript did not involve reporting of primary data obtained from studies of human or animal subjects. It is solely a comment manuscript.

RIGHTS & PERMISSIONS

2021 Higher Education Press
AI Summary AI Mindmap
PDF(72 KB)

Accesses

Citations

Detail

Sections
Recommended

/